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Background: The price of antiretroviral drugs (ARVs) in low income countries declined steadily in recent years. This
raises concerns about the commercial viability of the market of ARVs in low income countries.
Methods: Using 2 costing scenarios, we modeled the production cost of the most commonly used ARVs in low
income countries in 2010 and 2012, and assessed whether, at the median price paid by low income countries, their
manufacturers would still make profits. By interviews we consulted 11 generic manufacturers on the current state of
the ARV market, and on what would be required to ensure their continued commitment to supply ARVs to low
income countries.
Results: Using the lowest prices for active pharmaceutical ingredients (API) quoted to WHO, and applying
published assumptions about the production cost of ARVs, our baseline estimate was that Indian generic
manufacturers would have made profits on only 1 out of 13 formulations of ARVs in both 2010 and 2012, and
publicly owned manufacturers would have made profits on 5 and 3 out of 13 formulations in 2010 and 2012,
respectively. We needed to assume a 20% and a 40% lower API cost for our model to predict that publicly owned
and Indian manufacturers, respectively, would make profits on the sale of the majority of their ARVs. Between 2010
and 2012, we estimate that - across the ARV portfolio - the gross profit on sales of ARVs to low income countries
decreased with between 6% and 7% of their sales price. Generic manufacturers consider that current prices are
unsustainable. They suggested amendments to the tender procedures, simplified regulatory procedures, improved
forecasting, and simplification of the ARV guidelines as critical improvements to maintain a viable ARV market.
Conclusions: While recent price decreases indicate that there is still space for price reduction, our estimate that
gross profit margin on sales decreased by 6 to 7% between 2010 and 2012 lends credibility to assertions by generic
manufacturers that the ARV market in low income countries is under considerable price pressure. This might create
problems for the quality and/or the continued supply of ARVs to low income countries.
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At the end of 2011, more than 8 million people received
antiretroviral treatment. This represents 54% of the
estimated 14.8 million people eligible for treatment [1],
and represents major progress towards the target of
treating 15 million people by 2015, to which the global
community committed in the UN General Assembly in* Correspondence: nakakeeto@sfr.fr
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distribution, and reproduction in any medium2011 [2]. The dramatic scale up of antiretroviral treat-
ment was made possible thanks to the commitments
and action of countries and the donor community, but
also because of a steady decrease in the cost of the drugs
they use. When, ten years ago, it cost close to 10.000 $US
for a year’s treatment, the median cost of drugs used in
first line treatment in low income countries decreased to
between 57 $US (for the adult fixed dose combination
of stavudine, lamivudine and nevirapine) and 186 $US
(for the adult fixed-dose combination of tenofovir,
emtricitabine and efavirenz) per year in 2012 [3].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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income countries increased in value from $US 188 million
ARV in 2005 to $US 835 million in 2010, and the number
of manufacturers supplying World Health Organisation,
(WHO)-prequalified quality assured products increased
from 17 in 2005 to 26 in 2010 [4], generic manufacturers
increasingly assert that the current low prices and trends
to further reduce them seriously threaten market sustain-
ability [5].
We decided to verify their claims that current price
levels are unsustainable by analyzing their production
costs and profit margins, to interview them to document
their perception of what they consider are key constraints
in the low income country market for ARVs, and to
identify which interventions might be considered to
overcome them. This paper presents our analysis of the
ARV production costs and profits made from their sale
in low income markets, and reports on the outcome of
the interviews with the manufacturers.
Methodology
Pricing analysis
From WHO’s 2010 survey on the use of ARVs we
selected all WHO-recommended regimens which in
2010 were used by more than 95% of 1st line patients,
and the 2 most frequently used 2nd line regimens [6].
From the WHO Global Price Reporting Mechanism [3],
we identified which formulations (and dosages) were
most frequently used to administer those regimens. We
then calculated the quantity and the cost of APIs needed
to treat one patient for one year (365 days) with each of
those formulations, using the lowest API price quoted
by their manufacturers in the 2010 and 2012 WHO
surveys on the price and production capacity of APIs for
ARVs [7,8], and calculated their total production cost,
using 2 scenarios.
In the first scenario, “Indian producers”, we modeled
the total production cost for privately owned Indian
generic manufacturers. From the 2010 annual reports
of publicly listed Indian generic ARV manufacturers
(Cipla Ltd [9], Ranbaxy Laboratories [10], Strides Arcolab
Ltd [11] and Aurobindo Pharma Ltd [12]) we extracted
the expenditures incurred in the production of their
medicines (material cost, employee cost, operating and
other expenditures, research and development expenses,
interest, depreciation and amortization of goodwill), and
added the value of each expenditure category to obtain
their value across the 4 companies (Table 1). Across the
4 companies, the cost of materials - including API,
excipients and packaging - was 56.1% of the total pro-
duction cost. As the cost of excipients and packaging
materials was not reported separately in the annual
reports, we assumed that their cost would be the same
as that in Brazil, which we calculated to be 3.21 $USfor every 365 tablets produced ,from a paper by Eloan
Pinheiro et al. [13], as described below. As beyond the
cost of materials, the total production cost contained
on average 43.9% costs to cover employee costs, operat-
ing and other costs, research and development cost,
interest, and depreciation and amortization of goodwill,
we added 78.3% (43.9/56.1) to the cost of materials
(APIs, excipients and packaging) to calculate the total
production cost.
In the second scenario “Publicly owned producer”, we
modeled the total production cost for a publicly owned
production facility, using data from Brazil [13]. The cost
of the materials was calculated as the sum of the cost of
the API used, plus the cost of the excipients and pack-
aging. The cost of excipients and packaging was
calculated as 3.21 $US/365 tablets produced, summing
up the cost of excipients and packaging for each of the 7
formulations included in Table 1 from the paper on the
cost structure of the production of ARVs from Brazil
[13], and dividing it by 20 - the total number of tablets
included in a defined daily dose of each of the seven
formulations combined. To obtain the total production
cost, the cost of labor and equipment, quality control
and transport, and indirect costs needed to be added.
Together those amounted to 17.4%, or 468 $US, of the
total sales price of 2691 $US of the 7 formulations
included in the same table. Dividing this amount by 20 -
the total number of tablets included in a defined daily
dose of each of the seven formulations combined –
yielded 23.4 $US as the estimate of their average contri-
bution to the total production cost for 365 tablets.
Table 2 illustrates how the scenarios were used to cal-
culate the total production cost of one person-year of
lamivudine 150 mg plus zidovudine 300 mg combination
tablets.
Following calculation of the total production costs of
each formulation, we calculated whether, at the median
price paid for them by low income countries in 2010
and 2012 (taken from the WHO Global Price Reporting
Mechanism [3]), and under both scenarios, the compan-
ies producing them would have made profits or losses,
and we assessed whether our assessment of their profits
and losses would be materially altered if we varied the
cost of the APIs, in a univariate sensitivity analysis.
Finally, we assessed the evolution of their margins be-
tween 2010 and 2012, comparing arithmetic mean profit
margins across the ARVs considered in the sensitivity
analysis.
Interviews with manufacturers of generic antiretroviral
drugs
We consulted 11 manufacturers producing ARVs, as
finished formulations or as APIs (Aspen Pharmacare,
Aurobindo Pharma Ltd, Cipla Ltd, Desano, Emcure,
Table 1 Summary of the 2010 annual reports of publicly traded Indian ARV manufacturers (*)
CIPLA Ranbaxy (**) Strides Arcolab Aurobindo Total of 4 companies
Gross sales of goods (minus excise duty) 61,351 56,721 16,958 39,979 175,009
Expenditure % of expenditures % of expenditures % of expenditures % of expenditures % of expenditures
Material cost 28,604 54.1 21,709 46.2 8,508 52.4 23,286 76.9 82,107 56.1
Employee cost 4,642 8.8 7,761 16.5 2,249 13.8 3,036 10.0 17,688 12.1
Operating and other expenses 14,641 27.7 14,712 31.3 3,388 20.8 6,716 22.2 39,457 27.0
Research & Development Expenses 2,598 4.9 2,598 1.7
Interest 50 0.1 542 1.1 1,467 9.0 505 1.6 2,564 1.8
Depreciation and Amortization of goodwill 2,289 4.3 2,284 4.8 638 3.9 4,611 3.1
Total 52,824 100 47,018 100 16,250 100 30,291 100 146,383 100
% of sales % of sales % of sales % of sales % of sales
Gross Profit before taxes 8,527 13.9 9,703 17.1 1,858 11.0 9,688 24.2 28,626 16.4
(*) Amounts in million Rupees.




















Table 2 Production cost and profits made from lamivudine 150 mg plus zidovudine 300 mg tablets
Materials cost Zidovudine Lamivudine
Daily dose (mg) 600 300
Amount of API per person-year in kg (daily dose in mg X 365 days/1.000.000) 0.219 0.1095
Cost of API (per kg) (lowest quote in the 2010 WHO survey) 315 150
Cost of API per person-year (Amount of API per person-year in kg X cost of API per kg) 69.0 16.4
Cost of API per person-year of both APIs combined 85.4
Number of tablets/day required to administer a daily dose of zidovudine plus lamivudine 2
Cost of excipients and packaging (3.21 per 365 tablets X number of tablets/day X 365 days) 6.4
Subtotal materials cost per person-year 91.8
Non-materials cost per person-year (according to both scenarios) Indian manufacturer Publicly owned manufacturer
Indian manufacturer: 78.3% of materials cost 71.9 -
Publicly owned manufacturer: 23.4 X number of tablets/day - 46.8
Total production cost per person-year
Materials cost PLUS non-materials cost 163.7 138.6
Median price paid by low income countries per person- year in 2010 101.4
Profit or loss per person-year at API cost quoted to WHO in 2010 −62.3 −37.2
Profit or loss per person-year when API cost is:
20% less than quoted to WHO −31.9 −20.1
40% less than quoted to WHO −1.4 −3.1
60% less than quoted to WHO 29.0 14.0
(amounts in $US).
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Strides Arcolab Ltd and UCL) on the current state of the
ARV market, and steps which they consider necessary to




According to the 2010 WHO survey on ARV use [6], the
most frequently used first line regimens (with % of
patients on first line therapy using them) were lamivudine
plus stavudine plus nevirapine (27.7%), lamivudine plus
stavudine plus efavirenz (14%), lamivudine plus zidovu-
dine plus nevirapine (used by 26.8%), lamivudine plus zi-
dovudine plus efavirenz (11.4%), lamivudine plus tenofovir
plus efavirenz (10.6%), emtricitabine plus tenofovir plus
efavirenz (3.5%), and lamivudine plus tenofovir plus
nevirapine (2.7%). The two most frequently used second
line regimens (with % of patients using second line therapy
using them) were lamivudine plus tenofovir plus lopinavir
(boosted with ritonavir) (27.1%), and zidovudine plus
didanosine plus lopinavir (boosted with ritonavir) (25%).
Taking into account the relative volume of different
formulations sold to low income countries reported in
the WHO Global Price Reporting mechanism, we identi-
fied the 13 formulations listed in Table 3 as the most fre-
quently used formulations to administer those regimens.
Table 3 lists, under the “Indian manufacturer” and“Publicly owned producer” scenarios, the median price
paid by low income countries (from [3]), the lowest price
of the APIs quoted to WHO in 2010 and 2012 (from [7]
and [8]), our calculation of the total production cost,
and our estimate of profit or loss generated by the sale
of one person-year of each formulation, at 2010 and
2012 median prices. In addition the effect of lowering
the price of the active pharmaceutical ingredients by
20%, 40% and 60% is shown.
In the scenario “Indian manufacturers”, at an API
price equal to their lowest quoted price to WHO, only
the sale of didanosine 250 mg tablets is predicted to gen-
erate profit, in both 2010 and 2012. One needs to
assume a 20% lower API price for 6 formulations to gen-
erate profit in 2010, but at this reduced API cost, only 3
formulations are predicted to generate profit in 2012. In
2010 and 2012, 11 and 10 formulations, respectively, are
predicted to generate profit at a 40% decreased API
price. At a 60% lower API cost all formulations are
predicted to generate profits, in both years. Considering
the profit (or loss) margins made on aggregate sales
price of the 13 formulations combined, one needs to as-
sume an API price decrease of almost 40% to generate a
gross profit margin of 20% in 2010. By 2012, the gross
profit margin generated when the API cost is reduced by
40% is seen to have decreased to 14%, a 6% loss in 2 -
years. Across the different levels of API price, there is a
decrease in profit margin from 2010 to 2012 of 7%.
Table 3 Profits and losses made from the sale of antiretroviral drugs to low income countries

















Profit or loss at API cost
quoted to
WHO
20% 40% 60% quoted to
WHO
20% 40% 60%
less less less less less less
1) Scenario “Indian manufacturers”
Three drug combination tablets
[lamivudine 150 mg + stavudine 30 mg
+ nevirapine 200 mg], b.i.d
63 37 78 −15 −2 11 25 57 39 81 −28 −10 4 18
[lamivudine 150 mg + zidovudine
300 mg + nevirapine 200 mg] b.i.d.
131 87 166 −4 −4 27 58 119 90 171 −53 −21 11 43
[lamivudine 300 mg + tenofovir 300 mg
+ efavirenz 600 mg] q.d.
192 126 230 −38 7 52 97 162 102 187 −25 11 47 84
[emtricitabine 200 mg + tenofovir
300 mg + efavirenz 600 mg] q.d.
242 136 243 −1 47 94 142 186 126 224 −38 6 50 93
Two drug combination tablets
[lamivudine 150 mg + stavudine 30 mg]
b.i.d.
39 24 54 −15 −7 2 10 36 24 55 −19 −10 −1 7
[lamivudine 150 mg + zidovudine
300 mg] b.i.d.
101 73 142 −41 −23 3 30 94 75 145 −51 −25 2 29
[lamivudine 300 mg + tenofovir 300 mg]
q.d.
109 71 133 −24 2 27 52 65 58 109 −44 −23 −3 18
[emtricitabine 200 mg + tenofovir
300 mg ] q.d.
143 78 145 −2 26 54 82 87 73 136 −49 −23 3 29
[lopinavir 200 mg + ritonavir 50 mg],
4 tablets/day
433 405 745 −313 −169 −24 121 359 314 583 −223 −112 0 112
Single drug formulations
[efavirenz 600 mg] q.d. 56 55 103 −47 −28 −8 11 46 44 84 −37 −22 −6 9
[nevirapine 200 mg] b.i.d. 31 13 35 −4 1 6 10 30 16 40 −10 −5 1 7
[zidovudine 300 mg] b.i.d 88 57 113 −25 −5 15 36 82 59 117 −35 −14 8 29
[didanosine 250 mg] b.i.d 159 52 105 54 73 92 110 165 55 109 55 75 94 114
Summary
Column total 1787 1214 2292 −475 −82 351 784 1488 1074 2041 −557 −173 210 592
Arithmetic mean profit margin (%) −27 −5 20 44 −37 −12 14 40
Decrease in profit margin between 2010
and 2012 (%)
11 7 6 4
Average decrease in profit margin across





















Table 3 Profits and losses made from the sale of antiretroviral drugs to low income countries (Continued)
2) Scenario “Publicly owned producer”
Three drug combination tablets
[lamivudine 150 mg + stavudine 30 mg
+ nevirapine 200 mg], b.i.d
63 37 91 −28 −21 −13 −6 57 38.8 92 −35 −27 −20 −12
[lamivudine 150 mg + zidovudine
300 mg + nevirapine 200 mg] b.i.d.
131 87 140 −9 8 26 43 119 89.6 143 −24 −6 12 30
[lamivudine 300 mg + tenofovir 300 mg
+ efavirenz 600 mg] q.d.
192 126 153 40 65 90 115 162 102 128 34 54 74 95
[emtricitabine 200 mg + tenofovir
300 mg + efavirenz 600 mg] q.d.
242 136 159 83 109 136 162 186 126 149 37 62 86 111
Two drug combination tablets
[lamivudine 150 mg + stavudine 30 mg]
b.i.d.
39 24 77 −38 −33 −29 −24 36 24 77 −42 −37 −32 −27
[lamivudine 150 mg + zidovudine
300 mg] b.i.d.
101 73 127 −25 −18 −3 11 94 75 128 −34 −19 −4 11
[lamivudine 300 mg + tenofovir 300 mg]
q.d.
109 71 98 11 25 40 54 65 58 85 −19 −8 4 15
[emtricitabine 200 mg + tenofovir
300 mg] q.d.
143 78 105 38 54 70 85 87 73 99 −13 2 16 31
[lopinavir 200 mg + ritonavir 50 mg], 4
tablets/day
433 405 512 −79 2 83 164 359 314 374 −14 48 111 174
Single drug formulations
[efavirenz 600 mg] q.d. 56 55 81 −25 −14 −3 7 46 44 70 −24 −15 −6 2
[nevirapine 200 mg] b.i.d. 31 13 66 −35 −33 −30 −27 30 16 69 −40 −36 −33 −30
[zidovudine 300 mg] b.i.d 88 57 110 −22 −11 0 12 82 59 112 −30 −18 −6 5
[didanosine 250 mg] b.i.d 159 52 106 54 64 75 85 165 55 108 57 67 78 89
Summary
Column total 1787 1214 1825 −35 197 442 681 1488 1074 1634 −147 67 281 494
Arithmetic mean profit margin (%) −2 11 25 38 −10 4 19 33
Decrease in profit margin between 2010
and 2012 (%)
8 7 6 5
Average decrease in profit margin across
sensitivity analysis outcomes (%)
6
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the 13 formulations are predicted to return profits in
2010 and 2012, at the API prices quoted to WHO. One
needs to assume a 20% lower than quoted API cost for 7
and 5 formulations to return a profit, and at a 40% lower
API cost 8 and 7 formulations become profitable, in
2010 and 2012, respectively. At a 60% lower API cost, 10
formulations are predicted to generate profits in both
years. Considering the profit (or loss) made on aggregate
sales price of the 13 formulations combined, one needs
to assume an API price decrease of almost 20% to gener-
ate a gross profit margin of 11% in 2010, across the
formulations considered. By 2012, the aggregate gross
profit margin generated when the API cost is reduced
20% is seen to have decreased to 4%, a 7% loss in 2 years.
Across the different levels of API price, there is a
decrease in profit margin from 2010 to 2012 of 6%.
Interviews with manufacturers of generic antiretroviral
drugs
In their interviews the manufacturers assured us that
there is still a strong commitment to supply appropriate
treatments to HIV/AIDS patients in low income coun-
tries, as many acknowledged and pledged to continue
embracing their social obligations. On the other hand,
most manufacturers interviewed stated that they would
“Only stay in the ARV market if the business is profitable
in the longer term”.
The most frequently mentioned constraints included
rapidly decreasing profitability of the low income country
ARV market, difficult market entry, and limited access to
reliable forecasting information.
The competitive advantage of vertically integrated com-
panies (producing both API’s and finished formulations),
who control API prices and can base their quoted prices
for formulations on end- to- end margins was characterized
by several interviewees as unfair, as it eliminates companies
which cannot control API prices from receiving tender
awards. In addition, non-Indian manufacturers mentioned
export subsidies offered by the Indian Government to
Indian manufacturers and exporters as constraining
their ability to compete.
Elaborating on the rapidly decreasing profitability, they
stated that the prices for first line ARV drugs “are at the
bottom”; with average portfolio gross margins at 5 to 8
percent. They also mentioned that, while initially profit
margins on generic second line and new first line
products might reach 20 to 25 percent, they eroded
drastically between 2010 and 2012.
According to the manufacturers, the current low
prices for generic products discourage new market
entrants, placing reliance on a small number of compan-
ies to cater for greatly increased demand in the coming
years, while discouraging the very same companies tomaintain a strong presence. The companies interviewed
estimated that the industry has adequate formulation
capacity, but that, with new product opportunities aris-
ing in other therapeutic areas, it is increasingly difficult
to keep production capacity allocated to low margin
ARVs. While currently assigned API capacity would need
to increase by 40% to treat 20 million patients, even
maintaining current production levels was mentioned to
be problematic at current prices, in particular in India,
where current interest rates were reported to stand at 13
to 17% for major investment loans. One manufacturer
stated that an API plant normally has a production life
span of 7–8 years, and might cost 32 to 35 million $US to
replace – an estimate given without information on its
production capacity, but corroborated subsequently as a
“typical figure” by 2 additional manufactures. It was
mentioned that in the last 4 to 5 years there were no new
API market entrants, and that current API production
comes from plants which are nearing the end of their
normal production life span.
Elaborating on market entry difficulties, they pointed
out that – with new medicines taking between 3 to 5 years
after FDA or EMEA approval to launch in developing
countries, as it requires inclusion in WHO treatment
guidelines, prequalification and multiple registrations -
the attractiveness of the market is further curtailed. More-
over, slow and costly drug registration processes were
characterized as unsustainable for low volume products or
for countries with small numbers of patients.
The remedial actions suggested by the manufacturers
include, first, to alleviate the effects of the price pressure
under which they operate. Abolition of the lowest tender
price rule and sharing the market ( e.g., the lowest bid-
der to supply 60%, the second, third and fourth lowest
bidders to supply 20%, 10% and 10% respectively at the
price of the lowest bidder) would not increase the cost to
the buyer, but would enable companies to manage their
stocks and production of APIs and formulations with
less risk, and avoid distress sales when drugs are
approaching their shipping deadlines (well in excess of
1 year before they expire). In addition, there should be
no obligation to bid on all items in a tender – as most
companies do not produce all products required. Finally,
it would help if the clients paid on time: the example of
PEPFAR and its Supply Chain Management System, who
pays within 45 days, which in turn enables formulators
to pay their API suppliers in 90 days, and generates
positive cash flow, was cited as a positive example and
practice to be emulated. Country tenders, often marred
by late payments, irregular off takes and cash flow
problems, were cited as increasingly problematic.
Faster registration processes, including regional regu-
latory harmonization and fast track registration of
prequalified or stringent regulatory approved ARVs
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age inspections by national drug regulatory authorities
when facilities have been inspected by a stringent regu-
latory authority or WHO. Several interviewees also
articulated the need to further simplify antiretroviral treat-
ment guidelines, as the number of drug combinations in
present use was perceived to be excessive, requiring
too many registrations, with serious time and cost
implications.
Reliable demand forecasts and sharing of information
on future therapeutic developments between technical
agencies and pharmaceutical companies was also iden-
tified as a need to ensure that the development of
products fits the ARV recommendations. The need to
harmonize forecasts by WHO and the Clinton Health
Access Initiative was identified as an area which must
improve in the short term.
Finally, earlier access for generic manufacturers to new
drugs and new formulations from innovators and
launching new products in low income countries coinci-
dental with developed markets was cited by many as an
important priority.
Discussion
In the annual meeting of WHO and UNAIDS with ARV
producers in October 2011 [5], manufacturers stated
that for several ARVs the gross margin is now less than
10% - typically 5 to 8%. They pointed out that, as new
opportunities arise (they reported that in 2012 alone 67
medicines will come off patent in the USA) it is increas-
ingly difficult to convince manufacturers to expand or
even to maintain existing ARV production capacity. As
competitive markets do require a diverse offer, the in-
creasingly vocal statements by the producers sparked off
several assessments by the industry, and not-for-profit
organizations, such as UNITAID [4] and the Global
Fund.
Our own attempt to analyse whether producing ARVs
for low income countries was still profitable was
hampered by lack of transparency about the production
costs of ARVs. Key uncertainties concern the cost of the
APIs, and the structure of the manufacturing costs of
the generic producers.
The first major uncertainty is the cost of APIs to ARV
producers. We used the lowest price quoted for APIs
from consecutive surveys by WHO, in spite of the fact
that those prices were consistently on average 35% lower
than the prices quoted for the same APIs in the World
Trade Organization, WTO Market News Service [14].
We had to conclude, from our sensitivity analysis, and
taking into account that the companies still publicly
stated that they continued to make – albeit modest –
profits, that even those lowest quotes to WHO are
overestimated. This conclusion is also supported by acase documented in our interviews in which a vertically
integrated API manufacturer marked up the price of one
of its API to a formulator with at least 35% to ensure its
own competitiveness in a 2012 tender.
A second uncertainly is the cost structure of ARV pro-
duction in the leading ARV producing companies. While,
on average, the publicly quoted Indian ARV manufacturers
reported 43.9% expenditure on non-material costs, this is
much higher than the 17.4% non-material costs reported
from Brazilian manufacturers [13]. As non-materials
cost likely becomes less, as a proportion of the total
production cost, when volumes increase, as is the case
with antiretrovirals, we therefore likely overestimated
their magnitude in our assessment of the production
cost of the Indian manufacturers. Also hinting in this
direction was a statement from an Indian manufacturer
that costs across his first line portfolio were API 80%,
excipients 15%, and packaging 1%, leaving a 4% gross
margin. His non-materials cost was apparently so low
as to have been forgotten.
A final limitation of our costing analysis is that we added
a fixed amount to account for excipients and packaging
costs, to the cost of API, for every 365 tablets produced.
This is clearly suboptimal, as different formulations come
with different excipients, and their cost will change over
time. While this cost was derived from published data from
Brazil [13], it might be overestimated for Indian producers,
which operate on a much larger scale than their Brazilian
counterparts.
When considering how worried one should be about
the commercial viability of the ARV market in low
income countries, there are conflicting signals.
On one hand, there are signals that there is still scope
for price reduction, in particular for the newer formula-
tion products containing tenofovir. In December 2012, the
government of South Africa announced that it has secured
access to lower prices for several antiretroviral drugs,
including the fixed dose combination of emtricitabine,
tenofovir, and efavirenz for a substantially reduced price –
quoted as 89.37 Rand per patient per month, equivalent to
120 US$ per year of treatment [15]. It is hard to imagine
that the 3 companies (Aspen Pharmacare, Cipla Medpro
and Mylan Pharmaceuticals) which agreed to supply this
formulation would do so at a loss.
On the other hand, we have converging statements
that the gross profit margins on the first line portfolio
have decreased to between 5% and 8%, considerably less
than the average gross profit margin of 16% reported by
publicly quoted Indian ARV manufacturing companies
listed in Table 1, and less than the gross 14% margin
reported for a generic manufacturer in Brazil [13]. Our
assessment of the evolution of their profit margins
suggests that they might have lost 6 to 7% of their gross
profit margin on sales between 2010 and 2012 is in
Nakakeeto and Elliott Globalization and Health 2013, 9:6 Page 9 of 10
http://www.globalizationandhealth.com/content/9/1/6keeping with their assertions. This would explain why
their HIV product managers face challenges when
pleading with their senior management to expand ARV
production.
A second distress signal is that manufacturers are
beginning to drop out of more challenging markets.
CIPLA, the Indian company which started supplying
affordable ARVs to low income countries in 2002,
announced in July 2012 that, after shifting its export
portfolio away from the tender ARV business, will cut
down exposure to anti-HIV drugs, and shift it to high-
margin, complex products such as inhalers [16]. Also,
while a denial was posted in e-drug, in early 2012, the
Zimbabwean manufacturer Varichem was reported to
have stopped producing ARVs, and stated that it had not
supplied any ARVs to Zimbabwe since November 2010,
citing lack of local support [17,18].
Some suggestions to protect the future development of
the market for antiretroviral drugs in low income coun-
tries have been identified in assessments by UNITAID
and Médecins Sans Frontières (MSF). The UNITAID
Medicines landscape report identified, among others, the
need to secure API supply for antiretroviral medicines,
and suggested to focus on developing market intelligence
on API markets to identify suppliers, production cap-
acity, cost structures, intellectual property issues, and
relationships between API suppliers and finished prod-
uct manufacturers, and to support upstream API pro-
duction expansion where needed through incentives
[4]. Concurring with the manufacturers we interviewed,
their report further suggests generating and sharing
regular market forecasts at API and final product levels,
to improve transparency and minimize market uncer-
tainty for developers and manufacturers [4]. The 2012
“Untangling the Web” report by Médecins Sans Frontières
includes a strong focus on intellectual property as a tool
to sustain competitive markets, and, in pleading for fur-
ther price decreases, recognizes the need to maintain a
competitive environment for which the continued com-
mitment of generic manufacturers from India remains crit-
ical [19]. There is also agreement with the manufacturers ,
strongly articulated by WHO and UNAIDS in Treatment
2.0 initiative, that simplification of the treatment guidelines
is needed to increase access to antiretroviral therapy [20].
However, even if there remains uncertainty about
whether the prices in the ARV market for low income
countries have really bottomed out, increasing access
also requires that the views the companies which com-
pete with one another to supply the market be given ser-
ious consideration. This requires attention to how the
business is concluded, how fast they are paid, which
regulatory hurdles need to be overcome, and what
intelligence can be shared to create the global public
good that access to treatment for HIV represents.The opinions and actions of organizations such as
WHO, UNAIDS and the Global Fund in changing the
ways tenders are conducted, in pharmaceutical regula-
tion, and in forecasting will be critical in achieving the
goal – 15 million people on ARV treatment by 2015 –
which they helped formulate. However, it would help the
manufacturers too if they could be a bit more forthcom-
ing with information that would allow a better appraisal
of whether their prices are fair and viable.
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